Intel Corporation (NASDAQ: INTC) shares closed at $43.63 on Monday, February 23, 2026, down 1.09% from the previous session’s $44.11 finish, but the stock showed resilience in pre-market trading Tuesday, February 24, climbing about 1.4% to around $44.24 after news of a multi-year technical partnership with AI chip startup SambaNova Systems.

The modest decline capped a volatile period for the semiconductor giant, which has traded in a 52-week range of $17.67 to $54.60. Year-to-date in 2026, INTC is up roughly 18-20% from late-2025 levels, reflecting cautious optimism about new CEO Lip-Bu Tan’s turnaround efforts, though the stock remains well below its 2021 peak and faces persistent valuation and execution questions.

Intel’s market capitalization stands at approximately $217-220 billion, supported by a cash position and CHIPS Act funding but weighed down by ongoing foundry losses and competitive pressures in AI and data center chips. Trading volume on February 23 reached about 57 million shares, near average for the name.

The latest catalyst came Tuesday when Intel announced it is participating in SambaNova’s $350 million Series E funding round and entering a multi-year technical collaboration. SambaNova, a maker of generative AI chips, will adopt Intel server processors and graphics cards for its systems, while Intel gains exposure to advanced AI workloads. The deal follows reports of failed acquisition talks between the companies and underscores Intel’s push to strengthen its AI ecosystem amid dominance by Nvidia and competition from AMD.

CEO Lip-Bu Tan, who took the helm in late 2025, has emphasized partnerships and ecosystem building as part of Intel’s recovery strategy. The SambaNova tie-up provides a positive signal, but analysts note it is incremental rather than transformative given Intel’s broader challenges in foundry profitability and AI market share.

Recent performance has been choppy. After rallying to the mid-$50s in January 2026 on optimism around Tan’s leadership and foundry progress, shares pulled back sharply following weaker-than-expected Q1 2026 guidance in early February. The company projected Q1 revenue of $11.7 billion to $12.7 billion, below some estimates, reflecting supply constraints and soft PC demand.

Full-year 2025 results (reported earlier) showed revenue growth but persistent foundry losses exceeding $2.5 billion annually. Management targets foundry breakeven by 2027-2028, with customer commitments for the 14A process expected in the second half of 2026. An Analyst Day planned for Santa Clara in H2 2026 will detail how AI infrastructure spending translates to shareholder returns.

Analyst views remain divided. Consensus rating is Hold to Moderate Buy, with an average 12-month price target around $45-48 (implying limited upside from current levels). Recent notes include caution over Nova Lake CPU delays (now pushed beyond CES 2027) and Meta’s shift toward Nvidia for some CPU workloads, potentially pressuring Intel’s data center position. However, bulls highlight undervaluation, government support, and potential upside from foundry ramps and AI partnerships.

Institutional activity shows mixed flows: some funds increased stakes, while others trimmed amid uncertainty. Insider buying by executives has been modest but positive.

Looking ahead, the next major update is Q1 2026 earnings (expected late April), where investors will seek clarity on foundry progress, AI GPU traction (including Gaudi and upcoming Falcon Shores), and any new customer wins. The stock’s trajectory depends on execution against ambitious goals in a highly competitive landscape.

For now, Intel remains a high-risk, high-reward turnaround story. Its cash position and strategic shifts provide a foundation, but near-term volatility persists as the market weighs AI spending sustainability, foundry profitability, and competition from Nvidia, AMD, and custom silicon players.

Hims & Hers Health Inc. (NYSE: HIMS) shares tumbled sharply in trading on Tuesday, February 24, 2026, falling as much as 9% intraday to around $14.07-$14.40 after the telehealth company issued first-quarter 2026 revenue guidance that missed Wall Street estimates, citing regulatory headwinds to its compounded semaglutide offerings.

The stock closed the prior session (February 23) at $15.51, down 0.77%, with after-hours and pre-market action pushing it lower to reflect investor disappointment with the outlook. Volume spiked to over 18-43 million shares in recent sessions, well above average, as the reaction erased much of the recent recovery gains. Year-to-date in 2026, HIMS is down more than 50%, with the stock trading near its 52-week low of $13.74-$15.15 after peaking above $70 in mid-2025.

Hims & Hers reported fourth-quarter and full-year 2025 results on February 23, posting revenue of $617.8 million for Q4 (up 28% year-over-year) and full-year revenue of $2.35 billion (up 59%). Adjusted EBITDA reached $318 million for the year, with net income of $128 million and subscribers surpassing 2.5 million (up 13%). Q4 EPS of $0.08 beat consensus estimates of $0.02-$0.05, reflecting solid execution in personalized care, weight-loss products, and non-GLP-1 categories.

However, the company’s Q1 2026 guidance of $600 million to $625 million fell short of analyst expectations around $653 million. Management attributed a $65 million headwind to regulatory changes impacting compounded semaglutide shipping and availability. Full-year 2026 revenue guidance of $2.7 billion to $2.9 billion aligned with or slightly topped consensus of $2.74 billion, while adjusted EBITDA is projected at $300 million to $375 million (margin of 11-13%).

The miss on Q1 guidance overshadowed the beat, with analysts and investors focusing on the near-term impact of compounding restrictions. Hims & Hers vowed to maintain its 2030 revenue target of more than $6.5 billion, emphasizing growth in personalized non-weight-loss offerings, overseas expansion, and subscriber retention through AI-driven care.

BTIG Research downgraded the stock from Buy to Neutral on February 24, citing the regulatory pressure and softer short-term outlook. Other firms maintained cautious stances, though some bulls argue the pullback creates an attractive entry given long-term tailwinds in telehealth and personalized medicine. Consensus price targets range widely from the high $20s to $60+, with an average around $27-33 (implying significant upside from current levels for believers).

Hims & Hers has built a strong position in direct-to-consumer health, offering treatments for sexual health, hair loss, mental health, dermatology, and weight management via telehealth consultations and compounded medications. The GLP-1 weight-loss category drove rapid growth in 2025, but regulatory scrutiny on compounded versions of drugs like semaglutide (used in Ozempic/Wegovy) has introduced uncertainty.

The company continues to scale its platform, with 65% of users now receiving personalized care and revenue per subscriber rising 11% to $83. Balance sheet strength remains a positive: operating cash flow reached $300 million in 2025, with liquidity over $900 million and no significant debt.

The stock’s sharp decline reflects a classic growth-to-value rotation, where high-multiple names face pressure when near-term visibility softens. Despite the pullback, Hims & Hers maintains a forward-looking narrative centered on digital health innovation, subscriber loyalty, and expansion into new categories and markets.

Investors await further clarity on regulatory outcomes for compounded GLP-1s and progress on international growth. The next earnings report is expected in early May 2026, with focus on Q1 performance and updated 2026 commentary.

Hims & Hers remains a polarizing name: bulls see a scalable, high-margin platform with massive addressable market, while bears highlight regulatory risks, competition, and valuation compression in a tougher macro environment for growth stocks.

A company that makes self-defense products has spent the last few years moving much of its manufacturing to the U.S. and is finding the benefits extend beyond having the ability to put a “Made in America” label on their products.

Byrna Technologies, which makes non-lethal personal security devices that can launch plastic or chemical irritant rounds, moved its main manufacturing facility from South Africa to Indiana in 2021 and began finding qualified U.S. component suppliers to prevent supply chain disruptions like what transpired during the pandemic.

“There are over 100 components that go into our launchers, we wanted redundancy on all of them,” Byrna Technologies CEO Bryan Ganz told FOX Business. “Generally, the offshore manufacturers were a little bit less expensive, so they got the majority of the production.”

Byrna Technologies moved its main manufacturing facility from South Africa to Indiana in 2021. (Sam Wolfe/Bloomberg via Getty Images)

“But when it was evident that Donald Trump was going to be elected president, we said, ‘You know what, he’s been very, very vocal about tariffs, this is probably a good time for us to start the process of moving the supply chain back on-shore,’” Ganz said.

BYRNA TECHNOLOGIES CEO ‘PLEASED’ WITH TRUMP TARIFFS HITTING CHINESE RIVALS

“We started this even before the tariffs were announced. When the tariffs were announced, we were feeling pretty smart about ourselves that we had correctly surmised that we would be able to on-shore things,” he added.

Ganz said that while the process of onshoring more of Byrna’s supply chain before the Trump administration’s tariffs were implemented last year, the tariffs made domestic production more cost-effective and the onshoring process revealed other benefits.

“It was very interesting because not only was it much cheaper with the imposition of the tariffs to be producing in the U.S., but we also discovered all sorts of soft cost benefits,” he said.

Byrna Technologies moved its manufacturing back to the U.S. before President Donald Trump implemented tariffs. (Brendan Smialowski/AFP via Getty Images)

“When you’re supplying componentry from offshore, you either have air freight costs, you have lengthy ocean voyages – when you’re supplying it from a hundred miles away by truck, you can be much more responsive to changes in consumer demand. If I need to visit the factory because there’s a quality problem, I can do it.”

HOW SHOULD BUSINESSES APPROACH TARIFF REFUNDS?

He added that while Byrna continues to buy some of its accessories from offshore suppliers, the company has focused its onshoring effort on the most critical aspects of its product, such as the launcher itself and its ammunition.

“We’re making self-defense products and I think the quality of the product, the dependability of the product, is really important to our consumers, so the Made in America moniker is very, very meaningful for our type of product,” he explained.

Ganz noted that Byrna closed its ammunition manufacturing facility in South Africa and moved it to a newly built facility in Fort Wayne that’s five miles away from the company’s facility where its launchers are produced.

FORMER INTEL CEO WARNS US CHIP COMEBACK STILL HAS A LONG WAY TO GO

The company’s latest launcher, the Byrna CL, was made of 34% U.S. components prior to the reshoring effort, but the launcher is now made with 92% U.S. components.

“It’s not without some cost. We’ve seen a couple percentage points increase in our cost as a result of bringing it back to the U.S., because of course, we would have been making it in the U.S. to begin with if it was the same price,” Ganz said. “But our margins have remained within two percentage points – last year we were 62% and this year we were 60.5-61% – so it was a de minimis impact on the cost.”

Ganz added that the tariffs were a determining factor in some of its reshoring decisions due to the higher cost of the import levies.

GET FOX BUSINESS ON THE GO BY CLICKING HERE

“When we ship something up, even though it may have been 10% less expensive than building it here, not so when you put a 30% tariff on. I’m a very patriotic guy, I like making stuff here in America. On the other hand, we’re a public company, we have shareholders – we have to look at what’s in the best interest of our shareholders,” he said. “With the tariffs, it was clear that it became less expensive to build in the U.S. than to build offshore.”

Ganz added that Byrna maintains some component manufacturing abroad to keep redundancy in the supply chain to guard against vulnerabilities that would arise if a domestic facility were to go offline unexpectedly, but the onshoring push has brought the company’s overall supply chain into the 80%-90% range for domestically-sourced components.

Tesla Inc. (NASDAQ: TSLA) shares declined 3.2% on Monday, February 23, 2026, closing at $348.12 after trading in a range of $345.80 to $357.45. The drop came as investors digested the company’s fourth-quarter 2025 delivery figures released earlier in February and weighed ongoing uncertainty around production ramps, competition in electric vehicles, and CEO Elon Musk’s shifting priorities toward artificial intelligence and humanoid robotics.

Tesla’s market capitalization stood at approximately $1.11 trillion at Monday’s close, down from peaks above $1.3 trillion in late 2025. The stock has gained roughly 4% year-to-date in 2026 but remains volatile, trading about 28% below its all-time high of $488.54 (split-adjusted) set in December 2024. Average daily volume has hovered around 85-90 million shares in recent sessions, reflecting continued retail and institutional interest despite a cooling in the meme-stock fervor of prior years.

The latest catalyst was Tesla’s Q4 2025 production and delivery report, issued February 2, 2026. The company produced 495,570 vehicles and delivered 484,507 — both figures below Wall Street consensus estimates of approximately 510,000-515,000 deliveries. Full-year 2025 deliveries totaled 1.81 million vehicles, marking the first annual decline since 2011 and falling short of Musk’s earlier goal of 20-30% growth. The shortfall was attributed to factory retooling for refreshed Model Y production, softer demand in Europe and China, and intensified competition from BYD, Rivian, and legacy automakers.

Despite the miss, Tesla maintained strong profitability metrics. Adjusted operating income reached $3.2 billion in Q4, with automotive gross margins holding above 18% excluding regulatory credits. Energy storage deployments surged 157% year-over-year to 11.0 GWh, underscoring growth in the Megapack and Powerwall businesses. Free cash flow remained positive at $2.1 billion for the quarter, supported by a cash position exceeding $33 billion.

Musk used the earnings call to pivot attention toward future growth drivers beyond EVs. He reiterated that Optimus, Tesla’s humanoid robot, represents “the biggest product opportunity in history” and projected millions of units annually within five years. The company showcased Optimus performing household tasks at the “We, Robot” event in October 2025 and confirmed limited production for internal use in 2026, with external sales targeted for 2027. Musk also highlighted progress on Full Self-Driving (FSD) software, with version 13.2 rolling out to more users and unsupervised driving demos in Texas and California.

Analyst reactions were mixed. Morgan Stanley maintained an Overweight rating with a $430 price target, citing robotics and AI as transformative long-term catalysts. Wedbush kept an Outperform at $515, emphasizing energy storage and autonomy upside. However, GLJ Research reiterated a Sell rating with a $23 target, arguing that current valuation assumes flawless execution on unproven initiatives while core EV growth slows. Consensus price target sits around $385-390, implying 10-12% upside from current levels, with ratings split roughly 60% Buy, 30% Hold, and 10% Sell.

The stock’s recent weakness aligns with broader EV sector pressures. Global electric vehicle sales growth has moderated in 2025-2026, with incentives phasing out in some markets and charging infrastructure still lagging in others. Tesla faces heightened competition in China, where BYD overtook it as the world’s largest EV seller by volume in 2025. Price cuts implemented in late 2025 and early 2026 helped stabilize demand but compressed margins.

Tesla’s energy business continues to shine as a bright spot. Megapack deployments are scaling rapidly, with new factories in Shanghai and Texas coming online. The segment posted record profitability in Q4, with gross margins exceeding 30%. Analysts project energy storage could contribute 15-20% of total revenue by 2027-2028 if current trends hold.

Regulatory and legal headwinds persist. The National Highway Traffic Safety Administration continues investigating FSD-related crashes, while multiple class-action lawsuits allege misleading statements about autonomy timelines. Musk’s political involvement, including his role in the Department of Government Efficiency (DOGE) under President Trump, has sparked debate about potential conflicts of interest and regulatory favoritism.

Looking ahead, Tesla’s next major update is the Q1 2026 production and delivery report expected in early April. Wall Street anticipates around 420,000-440,000 deliveries for the quarter, reflecting seasonal softness and ongoing Model Y refresh impacts. The earnings call, scheduled for late April, will provide further color on Optimus timelines, Robotaxi progress, and energy growth.

For now, Tesla stock trades at a forward P/E of approximately 80-90x consensus 2026 EPS estimates of $3.80-$4.00, well above traditional automakers but justified by bulls as a bet on AI, robotics, and energy rather than pure EV sales. Bears argue the multiple leaves little room for error if autonomy or humanoid timelines slip.

As February 2026 draws to a close, Tesla remains a high-conviction, high-volatility name. Its trajectory hinges on execution across multiple moonshot bets — from FSD and Robotaxi to Optimus and energy storage — while navigating a maturing EV market and macroeconomic crosscurrents.

This article was written by

Follow

Analyst’s Disclosure: I/we have a beneficial long position in the shares of ET either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.